MedTrace Logo

Desmopressin Acetate 0.2 mg Tablets, Fasting

NCT00835211 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-09-11

Study results available
· View outcomes & findings →

Summary

The objective of this study was to compare the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg desmopressin acetate tablets following a 0.8 mg dose under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Desmopressin Acetate 0.2 mg Tablets

4 x 0.2 mg, single-dose fasting

DRUG

DDAVP® 0.2 mg Tablets

4 x 0.2 mg, single-dose fasting

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    lead INDUSTRY

Principal Investigators

  • Gaetano Morelli, M.D. · MDS Pharma Services

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2003-08-31
Completion
2003-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00835211 on ClinicalTrials.gov